#1 Clinical Trials Search in Europe

Blu-451

BLU-451 is an innovative drug being studied in clinical trials for patients with advanced cancers, particularly those with EGFR Exon 20 insertion mutations. This article explores the ongoing research into BLU-451’s safety, effectiveness, and potential benefits for patients with specific types of lung cancer and other related conditions.

Table of Contents

What is BLU-451?

BLU-451 is a new drug being studied for the treatment of advanced cancers, particularly those with specific genetic changes called EGFR Exon 20 insertion mutations[1]. This medication is currently undergoing clinical trials to determine its safety and effectiveness in treating patients whose cancer has not responded well to other treatments.

What conditions does BLU-451 target?

BLU-451 is primarily being studied for the treatment of:

  • Non-small cell lung cancer (NSCLC): This is the most common type of lung cancer, accounting for about 80-85% of all cases[1].
  • Metastatic lung cancer: This refers to lung cancer that has spread to other parts of the body[1].
  • Brain metastases: These are cancer cells that have spread from the original tumor to the brain[1].
  • Other advanced cancers with specific genetic mutations in the EGFR gene[1].

How does BLU-451 work?

BLU-451 is designed to target cancers with specific genetic changes in the EGFR (Epidermal Growth Factor Receptor) gene. In particular, it focuses on mutations called Exon 20 insertions and other atypical EGFR mutations[1]. These genetic changes can cause cancer cells to grow and spread more quickly. By targeting these specific mutations, BLU-451 aims to slow down or stop the growth of cancer cells.

The Concerto Clinical Trial

The main study for BLU-451 is called the Concerto trial. This is a Phase 1/2 clinical trial, which means it’s testing both the safety and effectiveness of the drug[1]. The trial is divided into two main parts:

  1. Phase 1: This part of the trial aims to find the safest and most effective dose of BLU-451. It includes:
    • Testing BLU-451 alone in patients with various advanced cancers
    • Testing BLU-451 in combination with other chemotherapy drugs (carboplatin and pemetrexed) in lung cancer patients
  2. Phase 2: This part of the trial will further test how well BLU-451 works in different groups of patients with lung cancer, including those who have tried other treatments before and those who haven’t[1].

How is BLU-451 administered?

BLU-451 is taken as a tablet by mouth. Depending on the study group, it may be taken once a day (QD) or twice a day (BID). The treatment is given in 21-day cycles[1]. In some parts of the study, BLU-451 is combined with other chemotherapy drugs that are given through an intravenous (IV) infusion.

Potential Benefits of BLU-451

The researchers are studying several potential benefits of BLU-451, including:

  • Tumor shrinkage: They will measure how many patients see their tumors shrink (called the Overall Response Rate or ORR)[1].
  • Longer-lasting responses: They’ll look at how long the drug keeps working (Duration of Response or DOR)[1].
  • Slowing cancer growth: They’ll measure how long the drug can keep the cancer from getting worse (Progression-Free Survival or PFS)[1].
  • Improved survival: They’ll study whether the drug helps patients live longer (Overall Survival or OS)[1].
  • Brain metastases: They’ll specifically look at how well the drug works for cancer that has spread to the brain[1].

Possible Side Effects

As with any new medication, one of the main goals of the clinical trial is to understand the potential side effects of BLU-451. The researchers will be closely monitoring patients for any adverse events (AEs) and determining how severe they are[1]. It’s important to note that the full range of possible side effects isn’t known yet, which is why this study is being conducted.

Aspect Details
Drug Name BLU-451
Study Type Phase 1/2 clinical trial
Target Conditions Advanced cancers with EGFR Exon 20 insertion mutations, primarily NSCLC
Administration Oral tablet, once or twice daily on a 21-day cycle
Study Phases Phase 1: Determine safe dose and initial effectiveness
Phase 2: Further evaluate effectiveness and safety
Combination Therapy BLU-451 with carboplatin and pemetrexed in some study arms
Key Outcomes Measured Safety, tumor response, duration of response, survival rates
Special Focus Effectiveness in patients with brain metastases

FAQ

  • What is BLU-451? BLU-451 is a new drug being tested in clinical trials for patients with advanced cancers, especially those with EGFR Exon 20 insertion mutations. It's taken as a tablet and is being studied both alone and in combination with other cancer treatments.
  • What types of cancer is BLU-451 being tested for? BLU-451 is primarily being tested for advanced lung cancers, particularly non-small cell lung cancer (NSCLC) with EGFR Exon 20 insertion mutations. It's also being studied in patients with other EGFR mutations and those with brain metastases.
  • How is BLU-451 given to patients in the trial? In the trial, BLU-451 is given as a tablet that patients take by mouth. Depending on the study phase, it may be given once or twice daily on a 21-day treatment cycle.
  • What are the main goals of the BLU-451 clinical trial? The main goals of the trial are to determine the safe dose of BLU-451, understand how it works in the body, and evaluate its effectiveness in shrinking tumors or stopping cancer growth in patients with specific types of advanced cancers.
  • Are there any other drugs being tested along with BLU-451? Yes, in one part of the study, BLU-451 is being tested in combination with two chemotherapy drugs called carboplatin and pemetrexed. This combination is being studied to see if it's more effective than BLU-451 alone for certain patients.

Ongoing Clinical Trials on Blu-451

  • Study of BLU-451 for Patients with Advanced Cancers Having EGFR Exon20 Insertion Mutations

    Not yet recruiting

    2 1 1
    Investigated diseases:
    Investigated drugs:
    Spain

Glossary

  • EGFR: Epidermal Growth Factor Receptor, a protein on cells that helps them grow. When EGFR is mutated in cancer, it can cause cells to grow uncontrollably.
  • Exon 20 Insertion Mutation: A specific type of change in the EGFR gene that can lead to lung cancer. It's less common than other EGFR mutations and can be harder to treat.
  • Non-Small Cell Lung Cancer (NSCLC): The most common type of lung cancer, accounting for about 80-85% of all cases.
  • Metastatic: Cancer that has spread from where it started to other parts of the body.
  • Brain Metastases: Cancer that has spread from its original location to the brain.
  • Tyrosine Kinase Inhibitor (TKI): A type of drug that blocks specific enzymes called tyrosine kinases, which are involved in cancer cell growth.
  • RECIST: Response Evaluation Criteria in Solid Tumors, a standard way to measure how well a cancer treatment is working.
  • Overall Response Rate (ORR): The percentage of patients whose cancer shrinks or disappears after treatment.
  • Progression-Free Survival (PFS): The length of time during and after treatment that a patient lives with cancer without it getting worse.
  • Overall Survival (OS): The length of time from the start of treatment that patients are still alive.

References